Heron Therapeutics
HRTX
Heron Therapeutics (HRTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.03
- EPS estimate
- −$0.01
- EPS surprise
- −500.00%
- Revenue surprise
- −10.72%
- Revenue
- $37.7M
- Revenue estimate
- $42.2M
- Reported
- Aug 10, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 10, 2026 | −$0.01 | −$0.03 | −500.00% | $37.7M | SEC |
| Q1 2026 | May 11, 2026 | −$0.02 | −$0.04 | −71.67% | $34.7M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.02 | −$0.02 | +0.00% | $40.6M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.02 | −$0.10 | −566.67% | $38.2M | SEC |
| Q2 2025 | Aug 8, 2025 | −$0.01 | −$0.02 | −100.00% | $37.2M | SEC |
| Q1 2025 | May 6, 2025 | −$0.01 | $0.01 | +261.29% | $38.9M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.03 | $0.02 | +165.36% | $40.8M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.04 | −$0.03 | +20.84% | $32.8M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.04 | −$0.06 | −52.67% | $36.0M | SEC |
| Q1 2024 | May 7, 2024 | −$0.07 | −$0.02 | +73.15% | $34.7M | SEC |
| Q4 2023 | Mar 12, 2024 | −$0.15 | −$0.07 | +54.49% | $34.2M | SEC |
| Q3 2023 | Nov 14, 2023 | −$0.29 | −$0.17 | +41.88% | $31.4M | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.22 | −$0.35 | −56.74% | $31.8M | SEC |
| Q1 2023 | May 11, 2023 | −$0.22 | −$0.27 | −24.77% | $29.6M | SEC |
| Q4 2022 | Mar 23, 2023 | −$0.32 | −$0.17 | +46.32% | $30.0M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.38 | −$0.38 | −1.06% | $26.6M | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.54 | −$0.55 | −2.61% | $27.6M | SEC |
| Q1 2022 | May 9, 2022 | −$0.49 | −$0.63 | −29.90% | $23.5M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.58 | −$0.54 | +6.36% | $20.7M | SEC |
| Q3 2021 | Nov 3, 2021 | −$0.61 | −$0.51 | +16.12% | $23.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Heron Therapeutics (HRTX) last report earnings?
Heron Therapeutics last reported on Aug 10, 2026, covering fiscal Q2 2026.
Did HRTX beat earnings estimates?
No. Heron Therapeutics reported EPS of −$0.03 for Q2 2026 against a −$0.01 estimate — a 500.00% miss.
How much revenue did HRTX report last quarter?
Heron Therapeutics reported $37.7M in revenue for Q2 2026, against a consensus estimate of $42.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.